All News

In this Q&A, Craig Serra, head of commercial solutions and partnerships within the clinical research business unit at Flatiron Health (affiliate of the Roche Group), shares his perspective on clinical research, the role of data, and Flatiron Health’s efforts to that end.

Online HCP community allows HCPs and researchers access to the latest breakthroughs in medicine and life sciences research.

Recent data and commentary offer insights into how biologics vs. small molecule patent protections under the Inflation Reduction Act pricing scenarios is impacting investing in the biotech sector.

The National Alliance of Healthcare Purchaser Coalitions releases resources for employers/health plan purchasers to offer insights on PBMs role in high prescription drug costs.

NORD goes on record that IRA’s MDPNP will lead to stifling of innovation for rare disease community.

The confirmatory study—which tracked 18 months of data—helped clear the way for new Alzheimer’s drug.

Newly-issued final guidance focuses on language used when communicating quantitative efficacy or risk information.

Service expected to help companies discover partners in funding.

Partnership to focus on developing immunotherapies for patients with cancer.

There are clear pathways that biopharma companies can take to sustain growth and remain competitive.

Complaints filed against CMS target the unconstitutionality of the Act, while the stifling of innovation in biopharma runs a parallel argument for numerous reasons

The collaboration will use results-based financing to achieve its goals.

This month, we deliver deep dives into the industry's commercial output and outlook and how drugmakers are faring in their public trust mandate—two areas where respective growth pursuits can often go hand-in-hand.

As conference season ramps up, it's a good time to reflect on the impact advances in pharma have on patients.

Indicates that reimbursement for new slate of Alzheimer’s treatments will occur only with the completion of studies to support full approval.

Agency hopes to update and improve its advisory committee composition and operations—to help FDA scientists “get the best advice possible.”

Amid drug pricing blame game, Congress advancing a range of reform efforts to manage and curb pharmacy benefit manager practices.

This year marks my first involvement in Pharmaceutical Executive’s Emerging Pharma Leaders (EPL) Awards, and what a ride it has been. We received so many wonderful nominations, and it’s always humbling to learn about some of the intricacies of the research that’s being done as well as the accomplishments of both current leaders and up-and-coming leaders.

The UK BioIndustry Association and Clarivate detail current economic trends in the UK Biotech Financing Report.

Agency hopes to attract more seasoned expertise in manufacturing; also looking to add field inspectors.

Janssen, Johns Hopkins Dermatology’s Ethnic Skin Fellowship Program partnership focuses on improving clinical care and advancing research for skin-of-color patients.

Amid continued tussling over drug costs, a new working group will review the government’s authority to revoke licenses for medical products.

Silicon Valley Bank has collapsed, leaving many biotechnology companies unsure of the future.

The importance of not over-expanding during development, launch.

Manufacturer to withdraw preterm birth drug, amid latest FDA push.

The rise of DOLs doesn’t mean pharma should upend KOL approach.

Latest investigation signals more scrutiny of pharmacy benefit managers and their role in treatment cost and coverage.